Clinical trials: Cancer Patient
Dupuytren's Contracture
Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Dupuytren's Contracture
Background: Dupuytren's contracture is a common hand problem that causes certain fingers to bend towards the palm. Patients with this condition cannot perform daily activities and many are unable to work.
- Trial name
- NCT00565019
- Testing
- Triamcinolone Acetonide
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- Sunnybrook Health Sciences Centre
Malignant Neoplasm of Breast
Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
Despite its aggressiveness and high incidence, to date, no targeted therapies exist for the treatment of triple negative breast cancer (TNBC).
- Trial name
- NIB (NCT03289819)
- Testing
- Pembrolizumab, nab-paclitaxel, Epirubicin
- Where
- 4 sites in Germany
- Volunteers
- 53 people
- Sponsor
- Institut fuer Frauengesundheit
Survival Outcomes
Effectiveness of Surgery for Improving Survival in Oligometastatic Breast Cancer Patients
Breast cancer is the most common malignancy in women, with stage IV disease at diagnosis in 5-10% of cases. Oligometastatic breast cancer (OMBC), defined as limited metastases (≤3-5 in ≤1-2 organs), may have better outcomes.
- Trial name
- SASI-MBC (NCT07586319)
- Testing
- surgery in accordance with current clinical guidelines, modified radical mastectomy or breast conservation surgery
- Where
- Pakistan
- Volunteers
- 110 people
- Sponsor
- Sharif Medical Research Center
Prostate Cancer
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy given with QS21 in treating patients who have progressive prostate cancer.
- Trial name
- NCT00003819
- Testing
- QS21, TF(c)-KLH conjugate vaccine, Thomsen-Friedenreich antigen
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor
Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in China
The primary objective is to evaluate the safety and, tolerabilitytolerance, pharmacokinetices and immunogenicity of escalating single doses and subsequent multiple dose of Gentuximab Injection in patients with late recurrence of…
- Trial name
- NCT03313219
- Testing
- Gentuximab Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Head and Neck Cancer, Unspecified Adult Solid Tumor, Protocol Specific
L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of L-778,123 in treating patients with recurrent or…
- Trial name
- NCT00003430
- Testing
- L-778,123
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Aspergillosis
Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis
The purpose of this study is to evaluate the therapeutic effectiveness of combination antifungal therapy (CAT) of voriconazole plus micafungin versus voriconazole plus placebo equivalent as primary therapy for invasive…
- Trial name
- NCT01207128
- Testing
- Voriconazole, micafungin
- Where
- 2 sites in United States
- Sponsor
- University of Arkansas
Recurrent Plasma Cell Myeloma
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
This phase I trial studies the side effects and best dose of dinaciclib and bortezomib when given together with dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement.
- Trial name
- NCT01711528
- Testing
- Bortezomib, Dexamethasone, Dinaciclib
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma, Tumor
Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers
In this study, we hope to evaluate the safety of PDT using temoporfin plus endoscopic stents in patients with inoperable bile duct cancers.
- Conditions
- Cholangiocarcinoma, Tumor, Klatskin Tumor
- Trial name
- PDT (NCT03003065)
- Testing
- Temoporfin
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Chinese University of Hong Kong
Colorectal Cancer, Colon Adenoma
A Randomized Prospective Trial Comparing Polyethylene Glycol and Sodium Picosulphate With Magnesium Citrate
Adequate bowel cleansing is important for a completeness of colonoscopy and detection of colon polyps. Inadequate bowel preparation leads to longer duration of colonoscopy and obscured mucosal visualization resulting in missed…
- Trial name
- NCT01778192
- Testing
- Polyethylene glycol, Sodium picosulphate with magnesium citrate
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Korea University Anam Hospital
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
Single Patient Expanded Access
- Trial name
- NCT04135092
- Testing
- Individual Patient TCR Transduced PBL, Cyclophosphamide, Fludarabine
- Sponsor
- National Institutes of Health Clinical Center (CC)
Bladder Cancer, Prostate Cancer
Occupational Situation and Return to Work of Urological Patients
This study will examine the work status of all adult patients admitted over a 6-month period to the University Hospital in Kraków, Poland, for treatment of urological diseases.
- Conditions
- Bladder Cancer, Prostate Cancer, Renal Cancer, Urinary Stones
- Trial name
- OCCURORTW (NCT07088536)
- Testing
- Occupational Status Survey and Telephone Follow-up and Quality-of-Life Assessment in a subset of patients
- Where
- Poland
- Volunteers
- 2,000 people
- Sponsor
- Jagiellonian University
Breast Cancer
A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients
This is the phase 2 portion of a phase 1/2 trial, testing the use of pemetrexed and cyclophosphamide in combination for the treatment of advanced breast cancer.
- Trial name
- NCT00190671
- Testing
- pemetrexed, cyclophosphamide
- Where
- 13 sites in Austria, Czechia and 4 more
- Volunteers
- 103 people
- Sponsor
- Eli Lilly and Company
Lung Cancer
Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer
Advanced non-small-cell lung cancer (NSCLC) patients without epidermal growth factor receptor (EGFR) mutations show a poor prognosis.
- Trial name
- NCT01623102
- Testing
- cisplatin and gemcitabine combination with Bevacizumab, Gemcitabine combined with cisplatin chemotherapy
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Ovarian Carcinoma, Ovarian Cancer
Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses
This study is performed to compare the diagnostic performance and cost-effectiveness of different diagnostic methods for differentiating benign from malignant adnexal (ovary or Fallopian tube) masses: the Risk of Malignancy Index…
- Conditions
- Ovarian Carcinoma, Ovarian Cancer, Ovarian Mass, Ovarian Cyst
- Trial name
- SUBSONiC (NCT02218502)
- Testing
- Ultrasound by general gynaecologist, Ultrasound by an expert ultrasonographist, DW-MRI
- Where
- 5 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- Maastricht University Medical Center
RAS Mutation, NF1 Mutation
PAS-004 in Patients With Advanced Solid Tumors
The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations.
- Conditions
- RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
- Trial name
- NCT06299839
- Testing
- PAS-004 Capsules, PAS-004 Tablets
- Where
- 5 sites in United States, Bulgaria and 1 more
- Volunteers
- 83 people
- Sponsor
- Pasithea Therapeutics Corp.
Multiple Myeloma
A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients
The primary reason for this study is to further assess safety and efficacy data of the bortezomib/melphalan/prednisone (BMP) regimen in previously untreated and transplant ineligible multiple myeloma patients
- Trial name
- NCT00799539
- Testing
- bortezomib, melphalan, prednisone
- Where
- 3 sites in Canada
- Sponsor
- Janssen-Ortho Inc., Canada
Pancreatic Cancer
Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer
The study focuses on advanced metastatic pancreatic cancer, testing a combination of low-dose anti-cancer drugs (G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) with the addition of Mitomycin C.
- Trial name
- GFLIPM (NCT06233877)
- Testing
- G-GLIP plus Mitomycin C
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Hirschfeld Oncology
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
This study aims to evaluate the efficacy and safety of adebrelimab combined with the AG regimen in patients with unresectable locally advanced or metastatic pancreatic cancer who have received at least one prior line of systemic…
- Trial name
- CSPAC-48 (NCT06916975)
- Testing
- Adebrelimab, AG
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Jin Xu
Malignancies, Acute Lymphoblastic Leukemia (ALL)
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary…
- Conditions
- Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma
- Trial name
- NCT03236857
- Testing
- chemotherapy, venetoclax
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 143 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.